Navigation Links
Depomed Announces Filing Of Shelf Registration To Replace Existing Shelf
Date:5/29/2012

MENLO PARK, Calif., May 29, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) announced that it has filed a "shelf" registration statement with the Securities and Exchange Commission. This will replace the Company's previously filed shelf registration statement, which will expire in June 2012 and includes the registration for the sale of common stock, preferred stock or debt securities.

The Company currently has no plan to issue any securities under the registration statement, and the terms of any future offering pursuant to the registration statement would be established at the time of the offering.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy these securities be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any such state.

About Depomed

Depomed, Inc. is a specialty pharmaceutical company with two approved and marketed products. Gralise ® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, www.depomed.com.

CONTACT: August J. Moretti

Depomed, Inc.

650-462-5900

amoretti@depomed.com


'/>"/>
SOURCE Depomed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Depomed To Present At Jefferies 2012 Global Health Care Conference
2. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
3. New 60,000 Square Foot Lease at the Pacific Research Center Signed by Biomed Realty and Depomed
4. Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex®
5. Endo Announces Resolution of Patent Litigation with Watson Pharmaceuticals Related to Lidoderm®
6. Horizon Pharma Announces Issuance of U.S. Patent Covering RAYOS (delayed-release prednisone)
7. Watson Announces Lidoderm® Patent Challenge Settlement
8. Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. Acacia Pharma Announces Excellent Phase II Results for APD421 in Post-Operative Nausea & Vomiting (PONV)
10. Mylan Announces Settlement Agreement in Patent Infringement Litigation Relating to Sunovions Brovana® Product
11. Uroplasty Announces Product Development and New Clinical Trial Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... 20, 2017 ResMed (NYSE: RMD ), BMC ... Winter Haven, Florida ) today announced they have agreed on ... 3B will be permitted to sell their existing products in exchange ... settlement payment to 3B to close the Florida ... an admission of liability or wrongdoing by any party. ...
(Date:1/21/2017)... 20, 2017  Today, during a plenary ... Pathways in Immunology, Growth Disorders and Cancer," ... INFI ) presented preclinical data for ... selectively inhibits phosphoinositide-3-kinase-gamma (PI3K-gamma). Preclinical data showed ... resistance to checkpoint inhibition by remodeling the ...
(Date:1/20/2017)... Research and Markets has announced the addition of the ... Creatinine, Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic Panel, Liver Panel, Renal ... report to their offering. ... The global clinical laboratory testing market is expected ... innovative solutions on the grounds of maximum efficiency and minimum error ...
Breaking Medicine Technology:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... bible in homes across the world. Yisrayl says this generation is a time like no ... to turn to the Bible. , Yisrayl says he does not want to sound like ...
(Date:1/20/2017)... ... January 20, 2017 , ... Bionic Sports Nutrition LLC, an American company devoted ... had a successful January ECRM Trade Show in Hilton Head, SC. , Bionic ... it to provide its products to all clients at reasonable prices. At the ECRM ...
(Date:1/20/2017)... Raton, FL (PRWEB) , ... January 20, 2017 , ... ... level of nutritional and bodybuilding supplements, announced it attended the January ECRM trade show ... respected bodybuilder and nutritional scientist who was determined to create a line of products ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well has ... 002. The drinks have been produced in collaboration with Zlatan Ibrahimovic and have ... workout. , After a successful launch in Sweden last year, the next generation ...
(Date:1/20/2017)... ... ... Chocolate Biscuit”: a biographical account following a man who went on to support his country ... Ivey, born in Lynn Haven, Florida and at the age of 5, his family moved ... he joined the Navy and got married right out of boot camp. , He ...
Breaking Medicine News(10 mins):